CoChat

Responsible innovation in human germline gene editing: Background document to the recommendations of ESHG and ESHRE

Open access
De Wert, Guido, Heindryckx, Björn, Pennings, Guido, Clarke, Angus, Eichenlaub-Ritter, Ursula, van El, Carla G., Forzano, Francesca, Goddijn, Mariëtte, Howard, Heidi C., Radojkovic, Dragica, Rial-Sebbag, Emmanuelle, Dondorp, Wybo, Tarlatzis, Basil C., Cornel, Martina C., On behalf of the European Society of Human Genetics and the European Society of Human Reproduction and Embryology · 2018 · European Journal of Human Genetics
Cited by 68

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Technological developments in gene editing raise high expectations for clinical applications, including editing of the germline. The European Society of Human Reproduction and Embryology (ESHRE) and the European Society of Human Genetics (ESHG) together developed a Background document and Recommendations to inform and stimulate ongoing societal debates. This document provides the background to the Recommendations. Germline gene editing is currently not allowed in many countries. This makes clinical applications in these countries impossible now, even if germline gene editing would become safe and effective. What were the arguments behind this legislation, and are they still convincing? If a technique could help to avoid serious genetic disorders, in a safe and effective way, would this be a reason to reconsider earlier standpoints? This Background document summarizes the scientific developments and expectations regarding germline gene editing, legal regulations at the European level, and ethics for three different settings (basic research, pre-clinical research and clinical applications). In ethical terms, we argue that the deontological objections (e.g. gene editing goes against nature) do not seem convincing while consequentialist objections (e.g. safety for the children thus conceived and following generations) require research, not all of which is allowed in the current legal situation in European countries. Development of this Background document and Recommendations reflects the responsibility to help society understand and debate the full range of possible implications of the new technologies, and to contribute to regulations that are adapted to the dynamics of the field while taking account of ethical considerations and societal concerns.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41431-017-0077-z

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 80

  1. Ledford H. Riding the CRISPR wave. Biologists are embracing the power of gene-editing tools to explore genomes. Nature. 2016;531:156–9. · DOI
  2. Cyranoski D. CRISPR gene-editing tested in a person for the first time. Nature. 2016;539:479. · DOI · Paper page
  3. European Medicines Agency. Issues identified by stakeholders: follow-up from EMA’s ATMP workshop. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2017/02/WC500220952.pdf. Accessed14 June 2017.
  4. Howard H, van El CG, Forzano F, et al. One small edit for humans, one giant edit for humankind? Points and questions to consider for a responsible way forward for gene editing in humans. Eur J Hum Genet. 2017 Nov 30. https://doi.org/10.1038/s41431-017-0024-z [Epub ahead of print] · DOI
  5. Reardon S. Global summit reveals divergent views on human gene editing. Nature. 2015;528:173. · doi:10.1038/528173a
  6. Reardon S US science advisers outline path to genetically modified babies. Nature 2017; https://doi.org/10.1038/nature.2017.21474 · doi:10.1038/nature.2017.21474
  7. De Wert G, Pennings G, Clarke A, et al. Human germline gene editing. Recommendations of the European Society of Human Genetics and the European Society of Human Reproduction and Embryology. Eur J Hum Genet. (In press/ submitted).
  8. De Wert G, Pennings G, Clarke A, et al. Human germline gene editing. Recommendations of the European Society of Human Genetics and the European Society of Human Reproduction and Embryology. Human Reproduction Open. (In press/submitted)
  9. Vassena R, Heindryckx B, Peco R, et al. Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells. Hum Reprod Update. 2016;22:411–9. · DOI
  10. Zhou X, Xin J, Fan N, et al. Generation of CRISPR/Cas9-mediated gene-targeted pigs via somatic cell nuclear transfer. Cell Mol Life Sci. 2015;72:1175–84. · DOI · Paper page
  11. Kang Y, Zheng B, Shen B, et al. CRISPR/Cas9-mediated Dax1 knockout in the monkey recapitulates human AHC-HH. Hum Mol Genet. 2015;24:7255–64. · DOI · Paper page
  12. Liu Z, Zhou X, Zhu Y, et al. Generation of a monkey with MECP2 mutations by TALEN-based gene targeting. Neurosci Bull. 2014;30:381–6. · DOI
  13. Kang X, He W, Huang Y, et al. Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing. J Assist Reprod Genet. 2016;33:581–8. · DOI · Paper page
  14. Shen B, Zhang J, Wu H, et al. Generation of gene-modified mice via Cas9/RNA-mediated gene targeting. Cell Res. 2013;23:720–3. · DOI · Paper page
  15. Chen S, Lee B, Lee AY, Modzelewski AJ, He L. Highly efficient mouse genome editing by CRISPR ribonucleoprotein electroporation of zygotes. J Biol Chem. 2016;291:1457–67.
  16. Hashimoto M, Yamashita Y, Takemoto T. Electroporation of Cas9 protein/sgRNA into early pronuclear zygotes generates non-mosaic mutants in the mouse. Dev Biol. 2016;418:1–9. · DOI · Paper page
  17. Boel A, Steyaert W, De Rocker N, et al. BATCH-GE: batch analysis of next-generation sequencing data for genome editing assessment. Sci Rep. 2016;6:30330. · DOI
  18. Goossens E, Van Saen D, Tournaye H. Spermatogonial stem cell preservation and transplantation: from research to clinic. Hum Reprod. 2013;28:897–907. · DOI · Paper page
  19. Woods DC, Tilly JL. Isolation, characterization and propagation of mitotically active germ cells from adult mouse and human ovaries. Nat Protoc. 2013;8:966–88. · DOI
  20. Hanna J, Cheng AW, Saha K, et al. Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Proc Natl Acad Sci USA. 2010;107:9222–7. · DOI · Paper page
  21. Duggal G, Warrier S, Ghimire S, et al. Alternative routes to induce naïve pluripotency in human embryonic stem cells. Stem Cells. 2015;33:2686–98. · DOI
  22. Van der Jeught M, O’Leary T, Duggal G, De Sutter P, Chuva de Sousa Lopes S, Heindryckx B. The post-inner cell mass intermediate: implications for stem cell biology and assisted reproductive technology. Hum Reprod Update. 2015;21:616–26. · DOI
  23. Hayashi K, Ohta H, Kurimoto K, et al. Reconstitution of the mouse germ cell specification pathway in culture by pluripotent stem cells. Cell. 2011;146:519–32. · DOI · Paper page
  24. Hayashi K, Ogushi S, Kurimoto K, Shimamoto S, Ohta H, Saitou M. Offspring from oocytes derived from in vitro primordial germ cell-like cells in mice. Science. 2012;338:971–5. · DOI · Paper page
  25. Zhou Q, Wang M, Yuan Y, et al. Complete meiosis from embryonic stem cell-derived germ cells in vitro. Cell Stem Cell. 2016;18:330–40. · DOI · Paper page
  26. Hikabe O, Hamazaki N, Nagamatsu G, et al. Reconstitution in vitro of the entire cycle of the mouse female germ line. Nature. 2016;539:299–303. · DOI · Paper page
  27. Hyslop LA, Blakeley P, Craven L, et al. Towards clinical application of pronuclear transfer to prevent mitochondrial DNA disease. Nature. 2016;534:383–6. · DOI · Paper page
  28. Jo A, Ham S, Lee GH, et al. Efficient mitochondrial genome editing by CRISPR/Cas9. Biomed Res Int. 2015;2015:305716. · DOI · Paper page
  29. Diot A, Dombi E, Lodge T, et al. Modulating mitochondrial quality in disease transmission: towards enabling mitochondrial DNA disease carriers to have healthy children. Biochem Soc Trans. 2016;44:1091–100. · DOI
  30. Yamada M, Emmanuele V, Sanchez-Quintero MJ, et al. Genetic drift can compromise mitochondrial replacement by nuclear transfer in human oocytes. Cell Stem Cell. 2016;18:749–54. · DOI · Paper page
  31. Zhang J, Liu H, Luo S, et al. Live birth derived from oocyte spindle transfer to prevent mitochondrial disease. Reprod Biomed Online. 2017;34:361–8. · DOI · Paper page
  32. Reddy P, Ocampo A, Suzuki K, et al. Selective elimination of mitochondrial mutations in the germline by genome editing. Cell. 2015;161:459–69. · DOI · Paper page
  33. Irie N, Weinberger L, Tang WW, et al. SOX17 is a critical specifier of human primordial germ cell fate. Cell. 2015;160:253–68. · DOI · Paper page
  34. Kashir J, Heindryckx B, Jones C, De Sutter P, Parrington J, Coward K. Oocyte activation, phospholipase C zeta, and human infertility. Hum Reprod Update. 2010;16:690–703. · DOI · Paper page
  35. Kashir J, Konstantinidis M, Jones C, et al. Characterization of two heterozygous mutations of the oocyte activation factor phospholipase C zeta (PLCζ) from an infertile man by use of minisequencing of individual sperm and expression in somatic cells. Fertil Steril. 2012;98:423–31. · DOI
  36. McCoy RC, Demko Z, Ryan A, et al. Common variants spanning PLK4 are associated with mitotic-origin aneuploidy in human embryos. Science. 2015;348:235–8. · DOI · Paper page
  37. Nuffield Council on Bioethics. Novel techniques for the prevention of mitochondrial DNA disorders: an ethical review. London: Nuffield Council on Bioethics; 2012. https://nuffieldbioethics.org/wp-content/uploads/2014/06/Novel_techniques_for_the_prevention_of_mitochondrial_DNA_disorders_compressed.pdf. Accessed 18 June 2017
  38. Castro RJ. Mitochondrial replacement therapy: the UK and US regulatory landscapes. J Law Biosci. 2016;3:726–35. · DOI
  39. Wolf DP, Mitalipov N, Mitalipov S. Mitochondrial replacement therapy in reproductive medicine. Trends Mol Med. 2015;21:68–76. · DOI · Paper page
  40. Dondorp WJ, Bolhuis P Mitochondriale ziekten: celkerntransplantatie en de embryowet. Tijdschrift voor Gezondheidsrecht 2002;26:2–9. · doi:10.1007/bf03055888
  41. Dyson A, Harris J, eds. Experiments on embryos. London/New York: Routledge; 1990.
  42. Green RM. The human embryo research debates. Bioethics in the vortex of controversy. Oxford: University of Oxford Press; 2001.
  43. De Wert G, Mummery C. Human embryonic stem cells: research, ethics and policy. Hum Reprod. 2003;18:672–82. · DOI · Paper page
  44. Dondorp W, De Wert G. Embryonic stem cells without moral pain? The Hague: Health Council of the Netherlands; 2005.
  45. ESHRE Task Force on Ethics and Law. The moral status of the pre-implantation embryo. Hum Reprod. 2001;16:1046–8. · doi:10.1093/humrep/16.5.1046
  46. Pera M, De Wert G, Dondorp W, et al. What if stem cells turn into embryos in a dish? Nat Methods. 2015;12:917–9. · DOI
  47. Hyun I, Wilkerson A, Johnston J. Revisit the 14-day rule. Nature. 2016;533:169–71. · DOI · Paper page
  48. ESHRE Task Force on Ethics and Law. Pennings G, de Wert G, Shenfield F, et al. Oocyte donation for non-reproductive purposes. Hum Reprod. 2007;22:1210–3. · doi:10.1093/humrep/dem025
  49. Hehir-Kwa JY, Claustres M, Hastings RJ, et al. Towards a European consensus for reporting incidental findings during clinical NGS testing. Eur J Hum Genet. 2015;23:1601–6. · DOI
  50. Health Council of the Netherlands. Incidental findings made during diagnosis in patient care. The Hague: Health Council of the Netherlands; 2014. https://www.gezondheidsraad.nl/en/task-and-procedure/areas-of-activity/optimum-healthcare/incidental-findings-made-during-diagnosis-in. Accessed 18 June 2017
  51. ESHRE Task Force on Ethics and Law. Pennings G, de Wert G, Shenfield F, et al. The welfare of the child in medically assisted reproduction. Hum Reprod. 2007;22:2585–8. · DOI
  52. McLaren A. IVF: regulation or prohibition? Nature. 1989;342:469–70. · DOI
  53. Savulescu J, Pugh J, Douglas T, Gyngell C. The moral imperative to continue gene editing research in human embryos. Protein Cell. 2015;6:476–9. · DOI · Paper page
  54. Sugarman J. Ethics and germline gene editing. EMBO Rep. 2015;16:879–80. · DOI
  55. Buchanan A, Brock DW, Daniels N, Wikler D. From chance to choice. Genetics & Justice. Cambridge: Cambridge University Press; 2000. · DOI · Paper page
  56. Juengst ET. “Alter-ing” the human species? Misplaced essentialism in science policy. In: Rasko JEJ, O’Sullivan GM, Ankeny RA, (eds.). The ethics of inheritable genetic modification: a dividing line? Cambridge, UK: Cambridge University Press; 2006. p. 149–58.
  57. Feinberg J. The child’s right to an open future. In: Aiken W, LaFollette H, (eds.). Whose child? Children’s rights, parental authority and state power. Totowa NJ: Rowman & Littlefield; 1980. p. 124–53.
  58. Habermas J. The future of human nature. Cambridge, UK: Polity Press; 2003.
  59. Annas G, Andrews L, Isasi R. Protecting the endangered human: toward an international treaty prohibiting cloning and inheritable alterations. Am J Law Med. 2002;28:151–78. · DOI · Paper page
  60. Carter AJR, Nguyen AQ. Antagonistic pleiotropy as a widespread mechanism for the maintenance of polymorphic disease alleles. BMC Med Genet. 2011;12:160. · DOI · Paper page
  61. De Wert G. Preimplantation genetic testing: normative reflections. In: Harper J, (ed.). Preimplantation genetic diagnosis. Cambridge: Cambridge University Press; 2009. p. 259–273. · DOI
  62. Hens K, Dondorp W, Geraedts J, De Wert G. Comprehensive pre-implantation genetic screening: ethical reflection urgently needed. Nat Rev Genet. 2012;13:676–7. · doi:10.1038/nrg3334
  63. Paul DB. What was wrong with Eugenics? Conflicting narratives and disputed interpretations. Sci & Educ. 2014;23:259–71. · doi:10.1007/s11191-012-9556-3
  64. Parens E, Asch Aeds. Prenatal testing and disability rights. Washington: Georgetown University Press; 2000.
  65. Shakespeare T. Disability Rights and Wrongs revisited. 2nd edn. Oxford: Routledge; 2014.
  66. Davis DS. Genetic dilemmas. Reproductive technology, parental choices and children’s futures. 2nd edn. Oxford: Oxford University Press; 2010.
  67. De Wert G, De Wachter G. Mag ik uw genenpaspoort? Ethische aspecten van dragerschapsonderzoek bij de voortplanting. Baarn: Uitgeverij Ambo; 1990. (in Dutch)
  68. Dondorp W, De Wert G, Bombard Y, et al. Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening. On behalf of the European Society of Human Genetics (ESHG) and the American Society of Human Genetics (ASHG). Eur J Hum Genet. 2015;23:1438–50. · DOI · Paper page
  69. ESHRE Task Force on Ethics and Law. De Wert G, Dondorp W, Pennings G, et al. Intrafamilial medically assisted reproduction. Hum Reprod. 2011;26:504–9. · doi:10.1093/humrep/deq383
  70. Health Council of the Netherlands. Heredity: Science and Society; on the possibilities and limits of genetic testing and gene therapy. The Hague: Health Council of the Netherlands; 1989. https://www.gezondheidsraad.nl/en/task-and-procedure/areas-of-activity/optimum-healthcare/heredity-science-and-society-on-the. Accessed 17 July 2017
  71. Comfort N. The science of human perfection. How genes became the heart of American medicine. New Haven & London, UK: Yale Univ. Press; 2012. · DOI · Paper page
  72. Janssens ACJW. Designing babies through gene editing: science or science fiction? Genet Med. 2016;18:1186–7. · DOI
  73. Anderson WF. Human gene therapy: why draw a line? J Med Philos. 1989;14:681–93. · doi:10.1093/jmp/14.6.681
  74. Harris J. Enhancing evolution. The ethical case for making better people. Princeton, USA: Princeton University Press; 2010. · doi:10.1515/9781400836383
  75. Wivel NA, Walters L. Germ-line gene modification and disease prevention: some medical and ethical perspectives. Science. 1993;262:533–8. · DOI
  76. Sandel M. The case against perfection. Ethics in the age of genetic engineering. Cambridge, USA: The Belknap Press of Harvard University Press; 2007. · DOI · Paper page
  77. Glover J. Choosing children. The ethical dilemmas of genetic intervention. Oxford, UK: Clarendon Press; 2006.
  78. Newson A, Wrigley A. Being human: the ethics, law, and scientific progress in genome editing. Aust Q. 2016;87:3–8.
  79. Von den Daele W. Mensch nach Mass? Ethische Probleme der Genmanipulation und Gentherapie. Munchen, Germany: Beck Verlag; 1985. (in German)
  80. Mertes H, Pennings G. Modification of the embryo’s genome: more useful in research than in the clinic. Am J Bioeth. 2015;15:52–53. · DOI

Metadata

Authors
De Wert, G., Heindryckx, B., Pennings, G., Clarke, A., Eichenlaub-Ritter, U., van El, C. G., Forzano, F., Goddijn, M., Howard, H. C., Radojkovic, D., Rial-Sebbag, E., Dondorp, W., Tarlatzis, B. C., Cornel, M. C., & On behalf of the European Society of Human Genetics and the European Society of Human Reproduction and Embryology
Venue
European Journal of Human Genetics
Published
2018-01-12
Volume
26
Issue
4
Pages
450-470
ISSN
  • 1018-4813 (ISSN-L)
  • 1476-5438
OpenAlex
W2783886181
Cited by
68
References
17
FWCI
4.75
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Responsible innovation in human germline gene editing: Background document to the recommendations of ESHG and ESHRE. https://app.cochat.ai/papers/10.1038/s41431-017-0077-z
The paper
De Wert, G., Heindryckx, B., Pennings, G., Clarke, A., Eichenlaub-Ritter, U., van El, C. G., Forzano, F., Goddijn, M., Howard, H. C., Radojkovic, D., Rial-Sebbag, E., Dondorp, W., Tarlatzis, B. C., Cornel, M. C., & On behalf of the European Society of Human Genetics and the European Society of Human Reproduction and Embryology. (2018). Responsible innovation in human germline gene editing: Background document to the recommendations of ESHG and ESHRE. European Journal of Human Genetics. https://doi.org/10.1038/s41431-017-0077-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.